Breaking News

Celltrion USA Launches Denosumab Biosimilars in the U.S.

The company expands its portfolio with Stoboclo and Osenvelt (denosumab-bmwo).

By: Rachel Klemovitch

Assistant Editor

Celltrion USA announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo), biosimilars referencing Prolia (denosumab) and Xgeva (denosumab), respectively, are commercially available in the United States. Stoboclo and Osenvelt are supported by Celltrion’s comprehensive patient support programs designed to help empower patients to navigate their treatment journeys. Stoboclo is available in 60 mg/mL injection and is approved: To treat postmenopausal women with osteoporosi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters